Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Shilpa Medicare Ltd - 530549 - Intimation U/R 30 Of The SEBI (LODR) Regulations- USFDA Approval

 This is to inform you that the Company has received U.S. Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL Injection USP, 40 mg/2mL and 100 mg/5mL (20mg/mL) Single Dose Vials. Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum. According to IQVIA MAT Q2 2018 data, the US market for Irinotecan HCL approximately USD 18 million. This is for your information and doing the needful.
01-01-2019
Bigul

SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Omprakash Inani
25-12-2018
Bigul

Shilpa Medicare Ltd - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deepak Kumar Inani
25-12-2018
Bigul

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Brijgopal Innani
27-11-2018
Bigul

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deepak Kumar Innani
27-11-2018
Bigul

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Om Prakash Innani
27-11-2018
Bigul

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ramakant Innani
27-11-2018
Bigul

Shilpa Medicare gets tentative USFDA nod for multiple sclerosis drug

 Shilpa Medicare has received tentative approval from the US health regulator for Dimethyl Fumarate delayed release capsules, used for the treatment of
16-11-2018
Bigul

Announcement Under Regulation 30 Of The SEBI (LODR) Regulations

 This is to inform you that the Company's ANDA (#210291) for Dimethyl Fumarate Delayed Release Capsules 120 mg & 240 mg has been granted tentative approval by FDA. Dimethyl Fumarate Delayed Release Capsules 120 mg & 240 mg is a generic of TECFIDERA, used in the treatment of patients with relapsing forms of multiple sclerosis. This ANDA is a first to file submission made on NCE-1 dated March 27, 2017. FDA review process was completed...
16-11-2018
Bigul

Announcement under Regulation 30 (LODR)-Acquisition

 We hereby inform you that the Board of Directors at their meeting held on 14.11.2018, has decided to acquire 5.22% in the target Company. The disclosure for the proposed Company enclosed herewith. This is for your kind information
15-11-2018
Next Page
Close

Let's Open Free Demat Account